



PHOSPHAGENICS

Company Announcement

Phosphagenics Signs Development Deal with Global Cosmetic Company

14 September 2011, Melbourne, Australia: Melbourne drug delivery technology company Phosphagenics Limited (ASX: POH, OTCQX: PPGNY) has entered into an agreement with a leading global cosmetic and dermatology company to conduct a human study on a new cosmetic product incorporating its TPM® platform delivery system.

Phosphagenics' CEO, Dr Esra Ogru, said the partnership with another leading cosmetic, high-caliber company is further endorsement of the efficacy of the company's platform technology.

"There is growing recognition from leading global cosmetics and dermatology companies that TPM® can be a major point of difference for them in the marketplace," she said.

"We have consistently demonstrated that TPM® enables superior delivery of active ingredients topically and transdermally and have proven the versatility of this technology by applying it both to cosmetic and pharmaceutical compounds."

Ends

Enquiries:

Dr Esra Ogru
Chief Executive Officer
Phosphagenics Limited
+61 3 9565 1119

David Segal
Investor Relations Manger
Phosphagenics Limited
+61 3 9565 1103

Rudi Michelson
Monsoon Communications
+61 3 9620 3333

About Phosphagenics

Phosphagenics is commercialising drug delivery applications based on its novel transdermal (drugs administered via skin) TPM® – Targeted Penetration Matrix technology. TPM® is a patient friendly and cost effective system used to deliver proven pharmaceutical and nutraceutical products.

The lead product advancing through clinical trials is an oxycodone matrix system for the relief of chronic pain.

Phosphagenics' shares are listed on the Australian Securities Exchange (POH) and its ADR – Level 1 program in the US is with The Bank of New York Mellon (PPGNY).

www.phosphagenics.com

www.elixia.com.au

Phosphagenics Limited

ACN 056 482 403 ABN 32 056 482 403

11 Duerdin Street, Clayton VIC 3168

PO Box 1415, Clayton South MDC VIC 3169 Australia

Tel: +61 (0)3 9565 1119 Fax: +61 (0)3 9565 1151

Web: www.phosphagenics.com Email: info@phosphagenics.com